DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer

Authors

Institutions

Publication Details

Journal
Journal of Gastrointestinal Oncology
Published
2026-02-01
DOI
https://doi.org/10.21037/jgo-2025-aw-959
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer

X. Chen, Jia Wei, Hongda Liu, Hao Qian et al.
Journal of Gastrointestinal Oncology
Gastric Cancer Management and Outcomes
article

DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer

X. Chen, Jia Wei, Hongda Liu, Hao Qian, Jiaguang Zhang, Yuting Ding, Hao Xu, Xinyi Zhang
article en

Abstract

No abstract available for this paper.
Journal of Gastrointestinal OncologyVol. 17(1)
Jiangsu Province Hospital (CN), Nanjing Medical University (CN)
Good health and well-being
Openalex Percentile: Top 58%
Gastric Cancer Management and Outcomes
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.